{"entity":{"id":"myeloid-derived-suppressor-cells","kind":"term","name":"Myeloid-derived suppressor cells (MDSCs)","aka":[],"tldr":"Immature immune cells that tumours summon to switch off T cells. Their numbers in blood predict worse immunotherapy outcomes.","summary":"Granulocytic (PMN-MDSC) and monocytic (M-MDSC) subsets; suppress T cells via arginase, iNOS, ROS, and PD-L1. Expanded by G-CSF, IL-6, and VEGF from tumours. Targets under study: CXCR2, STAT3, arginase inhibitors, PI3Kγ; also depleted by some chemotherapies (gemcitabine, 5-FU) and inhibited by PDE5 inhibitors in pilot trials. No medicine in OnCo is recorded as acting mainly on MDSCs. The four linked trials test SX-682, an oral CXCR1/2 inhibitor that blocks MDSCs from travelling into tumours in mouse models of head and neck cancer (Greene et al., Clinical Cancer Research 2020), with checkpoint inhibitors or enzalutamide.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Myeloid-derived_suppressor_cell","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Myeloid-derived_suppressor_cell"},{"label":"Greene et al., Inhibition of MDSC trafficking with SX-682, a CXCR1/2 inhibitor, enhances NK-cell immunotherapy in head and neck cancer models (Clinical Cancer Research 2020)","url":"https://doi.org/10.1158/1078-0432.ccr-19-2625"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["vegf","pdl1"],"drugs":[],"companies":[],"institutions":[],"pathways":["tumor-microenvironment","jak-stat"],"terms":[],"trials":["nct05570825","nct06149481","nct06228053","nct07322341"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Cancer biology"},"route":"/terms/myeloid-derived-suppressor-cells/","neighbours":{"target":[{"id":"cd11b","kind":"target","name":"CD11b","route":"/targets/cd11b/"},{"id":"cd14","kind":"target","name":"CD14","route":"/targets/cd14/"},{"id":"cd66b","kind":"target","name":"CD66b","route":"/targets/cd66b/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"pathway":[{"id":"complement-in-cancer","kind":"pathway","name":"Complement in cancer","route":"/pathways/complement-in-cancer/"},{"id":"jak-stat","kind":"pathway","name":"JAK-STAT signalling","route":"/pathways/jak-stat/"},{"id":"myeloid-suppression-axis","kind":"pathway","name":"Myeloid suppression: TAMs, MDSCs & don't-eat-me signals","route":"/pathways/myeloid-suppression-axis/"},{"id":"nutrient-competition-tme","kind":"pathway","name":"Nutrient competition & metabolic immunosuppression","route":"/pathways/nutrient-competition-tme/"},{"id":"pre-metastatic-niche","kind":"pathway","name":"The pre-metastatic niche","route":"/pathways/pre-metastatic-niche/"},{"id":"tumor-microenvironment","kind":"pathway","name":"Tumour microenvironment (TME)","route":"/pathways/tumor-microenvironment/"}],"trial":[{"id":"nct06149481","kind":"trial","name":"Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Can","route":"/trials/nct06149481/"},{"id":"nct06228053","kind":"trial","name":"Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer","route":"/trials/nct06228053/"},{"id":"nct07322341","kind":"trial","name":"SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer","route":"/trials/nct07322341/"},{"id":"nct05570825","kind":"trial","name":"SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer","route":"/trials/nct05570825/"}],"term":[{"id":"macrophage","kind":"term","name":"Macrophage","route":"/terms/macrophage/"}]}}